Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Nephrocare Health IPO Review & Investor Guide

By Jagat Joshi
December 10, 2025

Nephrocare Health IPO opens on December 10, 2025, and closes on December 12, 2025. The Nephrocare Health IPO price band is set between ₹438 to ₹460 per share, with a face value of ₹2 each. As per the RHP, the company plans to raise around ₹871.05 crores through an IPO.

For investors, deciding whether the Nephrocare Health IPO is a good investment can be quite challenging. If you are unsure and still thinking about whether to apply or skip this IPO, don’t worry. In this article, we present the top key factors and a detailed review of the Nephrocare Health IPO. This will help you analyze the strengths, risks, and financial details of the Nephrocare Health IPO, making your investment decision better.

About Company

Nephrocare Health Services Ltd. has been in the business of complete dialysis care through its clinics since 2010, with a large network of clinics across India and international markets. Its services consist of haemodialysis, home dialysis, mobile dialysis, and access to pharmacy support.

The company runs a total of 490 clinics, 447 in India and 43 across the Philippines, Uzbekistan, and Nepal as of March 31, 2025. Currently, the business is present in 269 towns in 21 Indian states and four union territories.

As of March 2025, the company had 5068 dialysis machines serving 29,281 patients and performing over 2.88 million dialysis sessions. Max, Fortis Escorts, Care Hospitals, Wockhardt, Paras, CMRI, Jehangir Hospital, and Ruby Hall Clinic are some of the major hospitals the company partnered with to run an in-house dialysis center.

Strengths

Nephrocare Health is India’s and Asia’s largest dialysis service provider with a 50% market share.

The company provides high-quality care through established clinical protocols and advanced technology.

The company has shown a strong focus on internal & inorganic growth.

Proven history of steady growth, strong profitability, and consistent returns.

The dialysis sector is low-risk because people need these treatments regularly, so demand stays steady.

Weaknesses

The company runs on healthcare professionals. Unable to retain or attract the new professionals could harm the business.

In the last few years, some of the subsidiaries have made losses. And they do not guarantee that they will make a profit in the future or continue to make losses.

The business depends on its brand and reputation, if it fails to maintain them or faces negative publicity, it could harm the business and negatively affect its performance.

The company faces a high attrition rate, meaning a lot of its employees are leaving the company within a year.

Nephrocare Health IPO Review

Reviewer	Recommendation
IPO Watch	May Apply
Kunvarji Finstock Pvt Ltd	Apply
Lakshmishree Investment & Securities Ltd	Apply
Axis Capital	Not Rated
Capital Market	May Apply
SBICAP Securities Limited	Apply
SMIFS Limited	Apply
Swastika Investmart Ltd	Apply

Nephrocare Health IPO Details

IPO Open Date:	December 10, 2025
IPO Close Date:	December 12, 2025
Face Value:	₹2 Per Equity Share
IPO Price Band:	₹438 to ₹460 Per Share
Issue Size:	₹871.05 Crores
Fresh Issue	₹353.40 crores
Offer-for-Sale	Up to 1,12,53,102 equity shares
Registrar	Kfin Technologies Ltd.
IPO Lead Managers	ICICI Securities Ltd. Ambit Pvt.Ltd. IIFL Capital Services Ltd. Nomura Financial Advisory & Securities (India) Pvt.Ltd.
Basis of Allotment	December 15, 2025
IPO Listing Date:	December 17, 2025
Listing	BSE, NSE

Financial Performance Trend Details

Particulars (in ₹ Cr)	30 Sep 2025	31 Mar 2025	31 Mar 2024
Total Income	483.97	769.92	574.72
EBITDA	110.31	166.64	99.66
EBITDA Margin	23.30%	22.05%	17.60%
PAT	14.23	67.10	35.13
PAT Margin	3.00%	8.88%	6.21%
Net Worth	716.06	594.21	423.55
Reserves & Surplus	704.14	578.68	408.57
Borrowings	207.04	225.80	243.37

Key Performance Indicator

KPI	Values
RoNW	13.19%
ROE	13.45%
ROCE	18.67%
Price to Book Value	7.72
EBITDA Margin	22.05%

Peer Comparison with the Company

Name of the Company	Face Value (₹)	Basic EPS (₹)	Diluted EPS(₹)	RONW (%)	P/E Ratio	NAV(₹)
Nephrocare Health	2	8.28	8.01	13.19%	[●]	59.56
Listed Peers
Narayana Health	10	38.90	38.90	21.77%	45.21	160.35
Jupiter Life Line Hospitals	10	29.47	29.47	14.27%	51.10	192.55
Rainbow Children Hospital	10	23.97	23.84	16.56%	56.84	134.69
Dr. Agarwal’s Healthcare	1	2.80	2.78	5.73%	179.42	55.13
Dr. Lal Path Labs	10	58.48	58.40	22.30%	52.47	245.26
Metropolis Healthcare	2	28.29	28.15	10.90%	69.48	236.34
Vijaya Diagnostics	10	13.95	13.92	17.99%	73.14	70.98

Promoters & Track Records, if any

Vikram Vuppala, born on December 14, 1976, aged 48 years, is one of the Promoters and the Chairman and Managing Director of the Company. He holds 10,533,523 Equity shares, representing 11.14% of the equity share capital in the company.

Bessemer Venture Partners Trust (“BVP Trust”) is a contributory irrevocable trust established under the Trust Act, 2001, that holds 9,366,870 shares, representing 9.90% of the company’s equity share capital.

Edoras Investment Holdings Pte. Ltd. was incorporated as Edoras Investment Holdings Pte. Ltd. on October 21, 2022, and holds 32,415,615 Equity shares, representing 34.28% of the equity share capital in the company.

Healthcare Parent Limited (“HPL”) holds 7,637,400 Equity shares, representing 8.08% of equity share capital.

Investcorp Private Equity Fund II (“IPEF II”) holds 6,993,870 Equity shares, representing 7.40% of equity share capital.

Investcorp Growth Opportunity Fund (“IGOF”) holds 622,395 Equity shares, representing 0.66% of equity share capital.

Industry Peer Group P/E ratio

In the Healthcare services sector, the P/E ratio ranges from a low of 45.21 to a high of 179.42, with an average of 75.38.

Expansion

The proceeds raised from the fresh issue will be used towards opening new dialysis clinics in India

A portion of the funds will be used towards Pre-payment, or scheduled repayment, of existing borrowings taken by the company.

Lastly, the remaining funds will be used for the company’s general corporate purposes.

Nephrocare Health IPO – Should You Apply or Not?

Nephrocare Health IPO offers a large dialysis clinic presence, great demand from chronic kidney patients, improving financial performance, and plans to use IPO proceeds for expansion and debt reduction to promote future growth. However, dependence on healthcare professionals, high attrition rate, and higher valuation are some of the major risks around the company.

As of December 8th, the GMP of the Nephrocare Health IPO is ₹0. Short-term investors can apply for the IPO for listing gain, given the positive market sentiment and attractive GMP. Investors who believe in the long-term growth of organised dialysis demand in India and have an interest in the healthcare sector can apply for the IPO on a long-term basis.

Please note:

Investors are advised to make their own decisions and apply entirely at risk. This article uses information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.